| Name | Title | Contact Details |
|---|
Midland States Bank is a community-based financial institution with over a century of history. As a subsidiary of Midland States Bancorp, Inc., headquartered in Effingham, Illinois, the bank is dedicated to supporting local businesses and residents. The bank offers a wide range of financial services, including commercial banking tailored for local businesses, wealth management with a focus on financial planning and investment services, and personal banking solutions that cater to individual needs. Midland States Bank emphasizes a personalized approach, aiming to be a supportive partner for customers during important life events. With a commitment to teamwork and community support, Midland States Bank promotes sustainable practices and social responsibility through its Environmental, Social, and Governance (ESG) initiatives. The bank continues to evolve under the leadership of CEO Leon J. Holschbach, focusing on enhancing profitability and competitiveness in the financial sector.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Wikifri is a nimble, aggressive, consulting firm founded by former Agile Technologies team members. We are focused on improving our clients businesses by bringing together deep insurance industry experience, the flexibility to build partnership-based engagement teams and technology expertise. Wikifri is founded by former Agile Technologies team members who are focused on a critical success factor to achieve breakthrough bottom line results for our clients by understanding their businesses and the difference they are going to make in their markets. We know successful technology investments help them achieve those goals. Our firms commitment to client success is demonstrated by our seasoned professionals industry experience, knowledge of the technology and insurance industry landscapes, and a long history of successful projects. Wikifri is committed to helping clients stay at the forefront of rapid industry changes by assisting them in the development of new markets and creating new efficiencies and capabilities for their organizations.
FinishWorks is the leading manufacturer and distributor of industrial wood and metal coatings. We are a recognized leader in supplying tailored coating solutions, combining trend-setting finish design with outstanding color consistency. FinishWorks is proud to be an RPM company. RPM International, Inc. (NYSE: RPM) is a global leader in specialty coatings that serves both the industrial and consumer markets.